Cellectis (NASDAQ:CLLS) Price Target Cut to $3.00 by Analysts at Wells Fargo & Company

Cellectis (NASDAQ:CLLS) had its price objective lowered by equities research analysts at Wells Fargo & Company from $4.00 to $3.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price target points to a potential upside of 63.93% from the stock’s current price.

A number of other equities analysts have also recently commented on the stock. Citizens Jmp reissued a “market perform” rating on shares of Cellectis in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research report on Friday, July 17th. Finally, Barclays began coverage on shares of Cellectis in a report on Thursday, May 28th. They set an “overweight” rating and a $9.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $7.00.

Cellectis Stock Performance

Shares of CLLS opened at $1.83 on Tuesday. The company has a market cap of $183.62 million, a PE ratio of -2.82 and a beta of 2.92. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.61. The stock has a 50-day moving average price of $3.00 and a 200-day moving average price of $3.34. Cellectis has a 12-month low of $1.75 and a 12-month high of $5.48.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.04. The company had revenue of $6.90 million for the quarter, compared to analysts’ expectations of $11.05 million. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%.

Hedge Funds Weigh In On Cellectis

A hedge fund recently bought a new position in Cellectis stock. Lido Advisors LLC purchased a new position in Cellectis S.A. (NASDAQ:CLLS) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. 63.90% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Cellectis

Here are the key news stories impacting Cellectis this week:

• Positive Sentiment: Cellectis plans to focus on in vivo gene-editing treatments for chronic diseases, a strategy that could create a more scalable platform and support longer-lasting therapies. Cellectis Announces Strategic Transformation to In Vivo Gene-Editing Company
• Neutral Sentiment: Citizens JMP reaffirmed its “market perform” rating, indicating limited near-term conviction while the company undergoes the transformation. CLLS Stock Heads for 14-Month Low After 40% Rout
• Negative Sentiment: Cellectis is exiting development of its lasme-cel and eti-cel programs as part of the pivot. Abandoning these cancer programs removes existing pipeline catalysts and contributed to the selloff. Cellectis Announces In Vivo Gene-Editing Transformation
• Negative Sentiment: Citizens JMP flagged delayed catalysts following the cancer-pipeline pivot, suggesting investors may face a longer wait for meaningful clinical or commercial progress. Delayed Cellectis Catalysts After Cancer Pipeline Pivot
• Negative Sentiment: The stock fell below its 50-day moving average and approached a 14-month low, signaling deteriorating momentum and potentially encouraging additional technical selling. Cellectis Share Price Crosses Below Fifty-Day Moving Average

Cellectis Company Profile

Cellectis SA (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.